Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase.


Journal

Journal of neurology, neurosurgery, and psychiatry
ISSN: 1468-330X
Titre abrégé: J Neurol Neurosurg Psychiatry
Pays: England
ID NLM: 2985191R

Informations de publication

Date de publication:
01 2019
Historique:
received: 22 05 2018
revised: 16 07 2018
accepted: 08 08 2018
pubmed: 19 9 2018
medline: 18 12 2019
entrez: 19 9 2018
Statut: ppublish

Résumé

To investigate the role of neuroinflammation in asymptomatic and symptomatic amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) mutation carriers. The neuroinflammatory markers chitotriosidase 1 (CHIT1), YKL-40 and glial fibrillary acidic protein (GFAP) were measured in cerebrospinal fluid (CSF) and blood samples from asymptomatic and symptomatic ALS/FTD mutation carriers, sporadic cases and controls by ELISA. CSF levels of CHIT1, YKL-40 and GFAP were unaffected in asymptomatic mutation carriers (n=16). CHIT1 and YKL-40 were increased in gALS (p<0.001, n=65) whereas GFAP was not affected. Patients with ALS carrying a CHIT1 polymorphism had lower CHIT1 concentrations in CSF (-80%) whereas this polymorphism had no influence on disease severity. In gFTD (n=23), increased YKL-40 and GFAP were observed (p<0.05), whereas CHIT1 was nearly not affected. The same profile as in gALS and gFTD was observed in sALS (n=64/70) and sFTD (n=20/26). CSF and blood concentrations correlated moderately (CHIT1, r=0.51) to weak (YKL-40, r=0.30, GFAP, r=0.39). Blood concentrations of these three markers were not significantly altered in any of the groups except CHIT1 in gALS of the Ulm cohort (p<0.05). Our data indicate that neuroinflammation is linked to the symptomatic phase of ALS/FTD and shows a similar pattern in sporadic and genetic cases. ALS and FTD are characterised by a different neuroinflammatory profile, which might be one driver of the diverse presentations of the ALS/FTD syndrome.

Identifiants

pubmed: 30224549
pii: jnnp-2018-318868
doi: 10.1136/jnnp-2018-318868
doi:

Substances chimiques

CHI3L1 protein, human 0
Chitinase-3-Like Protein 1 0
GFAP protein, human 0
Glial Fibrillary Acidic Protein 0
Hexosaminidases EC 3.2.1.-
chitotriosidase EC 3.2.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4-10

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: DRT received consultancies from Covance Laboratories (UK) and GE Healthcare (UK), received a speaker honorarium from GE Healthcare (UK), and collaborated with Novartis Pharma Basel (Switzerland).PO, PW, PS, SAS, FN, AEV, JDS, PMA, JK, AD, KFa, KFl, HJ, ML, KM, AK, JP, AS, DYH, JHW, ACL and MO report no competing interests.

Auteurs

Patrick Oeckl (P)

Department of Neurology, Ulm University Hospital, Ulm, Germany.

Patrick Weydt (P)

Department of Neurology, Ulm University Hospital, Ulm, Germany.

Petra Steinacker (P)

Department of Neurology, Ulm University Hospital, Ulm, Germany.

Sarah Anderl-Straub (S)

Department of Neurology, Ulm University Hospital, Ulm, Germany.

Frida Nordin (F)

Department of Pharmacology and Clinical Neurosciences, Umeå University, Umeå, Sweden.

Alexander E Volk (AE)

Institute of Human Genetics, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.

Janine Diehl-Schmid (J)

Department of Psychiatry, Technical University of Munich, Munich, Germany.

Peter M Andersen (PM)

Department of Neurology, Ulm University Hospital, Ulm, Germany.
Department of Pharmacology and Clinical Neurosciences, Umeå University, Umeå, Sweden.

Johannes Kornhuber (J)

Department of Psychiatry, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.

Adrian Danek (A)

Department of Neurology, LMU Munich, Munich, Germany.

Klaus Fassbender (K)

Department of Neurology, Saarland University, Homburg, Germany.

Klaus Fliessbach (K)

Department of Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn and DZNE Bonn, Bonn, Germany.

Holger Jahn (H)

Department of Psychiatry, University Hospital Hamburg, Hamburg, Germany.

Martin Lauer (M)

Department of Psychiatry and Psychotherapy, University of Würzburg, Würzburg, Germany.

Kathrin Müller (K)

Department of Neurology, Ulm University Hospital, Ulm, Germany.

Antje Knehr (A)

Department of Neurology, Ulm University Hospital, Ulm, Germany.

Johannes Prudlo (J)

Department of Neurology, University of Rostock, and German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany.

Anja Schneider (A)

Department of Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn and DZNE Bonn, Bonn, Germany.

Dietmar R Thal (DR)

Department of Neuroscience, KU Leuven and Department of Pathology, UZ Leuven, Belgium.
Laboratory of Neuropathology, Institute of Pathology, Ulm University, Ulm, Germany.

Deniz Yilmazer-Hanke (D)

Department of Neurology, Ulm University Hospital, Ulm, Germany.

Jochen H Weishaupt (JH)

Department of Neurology, Ulm University Hospital, Ulm, Germany.

Albert C Ludolph (AC)

Department of Neurology, Ulm University Hospital, Ulm, Germany.

Markus Otto (M)

Department of Neurology, Ulm University Hospital, Ulm, Germany markus.otto@uni-ulm.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH